These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 2823236)

  • 21. Heparin inhibition of endothelial cell proliferation and organization is dependent on molecular weight.
    Khorana AA; Sahni A; Altland OD; Francis CW
    Arterioscler Thromb Vasc Biol; 2003 Nov; 23(11):2110-5. PubMed ID: 12920044
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Binding of low-molecular-weight heparin to aortic endothelium in rabbits.
    Gensini GF; Fortini A; Lombardi A; Pesciullesi E; Pieroni C; Neri Serneri GG
    Haemostasis; 1984; 14(6):466-72. PubMed ID: 6534819
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Heparin, low molecular weight heparin, and derivatives in thrombosis, angiogenesis, and inflammation: emerging links.
    Mousa SA
    Semin Thromb Hemost; 2007 Jul; 33(5):524-33. PubMed ID: 17629850
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Specific heparin fractions suppress endothelin-1 production in cultured human umbilical vein endothelial cells.
    Reantragoon S; Arrigo LM; Seoud MM; Dweck HS; Rosenfeld L
    Arch Biochem Biophys; 1994 Nov; 314(2):315-22. PubMed ID: 7979371
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A functional assay for heparin in serum using a designed synthetic receptor.
    Wright AT; Zhong Z; Anslyn EV
    Angew Chem Int Ed Engl; 2005 Sep; 44(35):5679-82. PubMed ID: 16086350
    [No Abstract]   [Full Text] [Related]  

  • 26. Combined coagulation phase-directed factor Xa inhibition with heparin compounds and DX-9065a - a direct and selective antagonist.
    Becker RC; Alexander J; Li YF; Bovill E; Spencer FA; Robertson TL; Kunitada S; Dyke CK; Harrington RA
    Thromb Haemost; 2004 Dec; 92(6):1229-31. PubMed ID: 15622616
    [No Abstract]   [Full Text] [Related]  

  • 27. [Low molecular weight heparin CY 222 (Choay) potentiates the thrombolytic effect of 1-PA in rabbits with experimental thrombosis of the jugular vein].
    Juhan-Vague I; Stassen JM; Alessi MC; de Cock F; Serradimigni A; Collen D
    J Mal Vasc; 1987; 12 Suppl B():64-5. PubMed ID: 2834493
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Low molecular weight heparin fractions. Comparative preclinical study of various parameters].
    Fareed J
    J Mal Vasc; 1987; 12 Suppl B():59-63. PubMed ID: 2834492
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Capillary zone electrophoresis investigation of the interaction between heparin and granulocyte-colony stimulating factor.
    Liang A; He X; Du Y; Wang K; Fung Y; Lin B
    Electrophoresis; 2004 Mar; 25(6):870-5. PubMed ID: 15004848
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Low molecular weight heparin (CY 222) levels during hemodialysis sessions. Comparison of various chromogenic and chronometric methods. Problem of standardization].
    Roussel B; Dieval J; Bayrou B; Delobel J
    J Mal Vasc; 1987; 12 Suppl B():85-9. PubMed ID: 2834499
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Minimum fragments of the heparin molecule able to produce the accumulation and change of the sulfation pattern of an antithrombotic heparan sulfate from endothelial cells.
    Pinhal MA; Santos IA; Silva IF; Dietrich CP; Nader HB
    Thromb Haemost; 1995 Oct; 74(4):1169-74. PubMed ID: 8560430
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Heparin].
    Sakuragawa N
    Nihon Rinsho; 1995 Feb; 53 Su Pt 1():1060-3. PubMed ID: 8753622
    [No Abstract]   [Full Text] [Related]  

  • 33. A novel vascular endothelial growth factor heparin-binding domain substructure binds to glycosaminoglycans in vivo and localizes to tumor microvascular endothelium.
    El-Sheikh A; Liu C; Huang H; Edgington TS
    Cancer Res; 2002 Dec; 62(23):7118-23. PubMed ID: 12460934
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oral heparins.
    Hiebert LM
    Clin Lab; 2002; 48(3-4):111-6. PubMed ID: 11934211
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Equivalent effective doses of heparin and low molecular weight heparin(oid)s in haemodialysis for chronic renal failure.
    Lane DA; Ireland H; Tew CJ; Flynn A; Curtis JR
    Acta Chir Scand Suppl; 1988; 543():101-4. PubMed ID: 2847457
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interaction of immobilised unfractionated and LMW heparins with proteins in whole human plasma.
    Zammit A; Pepper DS; Dawes J
    Thromb Haemost; 1993 Dec; 70(6):951-8. PubMed ID: 8165617
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Technetium 99m labelled heparin: pharmacokinetics and tissue distribution in rats after vascular surgery.
    Colas-Linhart N; Berthelot JL; Ducret A; Petiet A; Bok B
    Biomed Pharmacother; 1987; 41(4):189-91. PubMed ID: 3620586
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Experimental arterial microsutures. Evaluation of the risks of thrombosis using technetium 99-labeled heparin].
    Berthelot JL; Colas-Linhart N; Petiet A; Bok B
    Neurochirurgie; 1986; 32(6):501-6. PubMed ID: 3547158
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Influence of a low-molecular-weight heparin derivative on the nitric oxide levels and apoptotic DNA damage in adriamycin-induced cardiac and renal toxicity.
    Deepa PR; Varalakshmi P
    Toxicology; 2006 Jan; 217(2-3):176-83. PubMed ID: 16242830
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pathophysiology of thromboembolism and its modulation by low-molecular-weight heparins.
    Breddin HK
    Semin Thromb Hemost; 1996; 22 Suppl 1():25-7. PubMed ID: 8807725
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.